Veritable’s Nektar Therapeutics NKTR Stock Holding History

Veritable’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,223	Closed	-$315K	–	766
2016 Q3	$315K	Buy	1,223 +23	+2%	+$5.92K	0.01%	569
2016 Q2	$256K	Buy	+1,200	New	+$268K	0.01%	604

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Veritable's NKTR Position: Q4 2016 in Review

Veritable sold out of Nektar Therapeutics (NKTR) in Q4 2016, closing a stake of 1,223 shares — an estimated $315K sold.

Veritable first reported a position in NKTR in Q2 2016 and held it in 2 quarters. The position peaked at $315K in Q3 2016. 199 funds tracked by Wall St. Rank hold NKTR as of Q4 2016.

Veritable reported no remaining Nektar Therapeutics position as of Q4 2016 after selling out during the quarter.
Veritable sold 1,223 Nektar Therapeutics shares in Q4 2016, an estimated $315K.
Veritable first reported a position in Nektar Therapeutics in Q2 2016 and held it in 2 quarters.
Veritable's Nektar Therapeutics position peaked at $315K in Q3 2016.
199 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2016.

Based on Veritable's 13F filing for Q4 2016, filed 14 Feb 2017.